Aktuellt
SENASTE
Redeye is overall positive to the second interim analysis from Vicore’s phase II trial in IPF with drug candidate C21, that largely confirms the previous efficacy data in a somewhat larger sample. We reiterate our base case of SEK 78 and will participate in today’s call before we likely return with an additional take.
LÄS MER
